Document center
A hand picked selection of interesting presentations and info
Zero-tolerance code of conduct. Counteracting gender-based violence, including sexual harassment, in the EU research and innovation system
This document was developed by the ERA Forum Sub-group ‘Inclusive Gender Equality in the ERA’, in close cooperation with the European Commission. It aims to address incidents of gender-based violence in research and higher education environments by setting out a common approach, definitions, and a list of principles to guide Member States and other stakeholders and individuals, to create a European Research and Innovation environment free from all forms of gender-based violence, based on the values of gender equality and inclusiveness, respect, dignity and safety. (from the report’s back cover)
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
